SHANGHAI, Dec. 12, 2023 /PRNewswire/ — Dizal presented compelling data from its robust portfolio of hematological oncology at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego, California from December 9-12. The data showcased updated results of Dizal’s two leading assets: golidocitinib, the first and only JAK1 selective inhibitor for the treatment of peripheral T-cell lymphoma (PTCL), and DZD8586, a first-in-class LYN and BTK dual inhibitor for the treatment of relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). This underscores Dizal’s dedication to developing and delivering innovative, life-changing medicines in the field of hematological oncology.

Golidocitinib

The first and only JAK1 selective inhibitor for the treatment of PTCL

Golidocitinib, a novel JAK1-only inhibitor developed by Dizal, is currently in the NDA stage for the treatment of r/r PTCL. The China National Medical Products Administration (NMPA) recognized its potential and granted it Priority Review in September 2023. Notably, golidocitinib stands as the world’s first and only highly selective JAK1 inhibitor specifically developed for PTCL. Furthermore, it has obtained Fast Track Designation from the U.S. Food and Drug Administration (FDA), positioning it as the first Chinese innovative PTCL drug to receive this designation.

The efficacy of golidocitinib in PTCL was highlighted at 2023 ASH, with two studies being selected for presentation. Particularly noteworthy is the multinational, pivotal study of golidocitinib for the treatment of r/r PTCL (JACKPOT8 PART B), which was selected for oral presentation and simultaneously published in the peer-reviewed journal The Lancet Oncology (Impact Factor: 54.4).

The potential best-in-class treatment option for r/r PTCL

There is no consensus on the standard treatment for r/r PTCL and the 5-year survival rate is below 30%. The results of JACKPOT8 PART B study revealed that golidocitinib demonstrated superior and durable clinical benefits in the treatment of r/r PTCL with a favorable safety profile that outperformed existing treatment options. Per independent review committee (IRC) assessment, golidocitinib achieved an overall response rate (ORR) of 44.3% and a complete response rate (CRR) of 23.9%. Both were more than double that of existing treatment options. Tumor responses were observed across various PTCL subtypes. The responses were durable, with the median duration of response (mDoR) of 20.7 months. This is higher than the DoR observed with existing therapies, which is typically below 12 months. The median progression-free survival (mPFS) was 5.6 months, and the median overall survival (mOS) was 19.4 months and still ongoing.

Promising and durable efficacy in PTCL after first-line systemic therapy

Approximately 40% of patients with complete response (CR) and 80% of patients with partial response (PR) have disease relapse within 2 years after initial tumor response. These patients currently lack a standard maintenance therapy.

JACKPOT 26 is a phase 2, single-arm, multicenter study to evaluate the safety and efficacy of golidocitinib for maintenance treatment after first-line therapy. At the data cut-off date of October 12, 2023, in the cohort of patients achieving CR post first-line therapy, median disease-free survival (DFS) has not been reached, with 76.7% patients still event free. In the cohort of patients achieving PR post first-line therapy, median DoR has not been reached, with 33% of patients achieving a CR and 85.7% of patients still responding to the treatment. The median PFS was 16.7 months. The treatment-related adverse events (TRAEs) observed in this study were similar to those previously reported for golidocitinib and were clinically manageable and reversible.

DZD8586

A first-in-class non-covalent LYN and BTK dual inhibitor with excellent blood-brain barrier (BBB) penetration

DZD8586 is a rationally designed, oral, non-covalent, LYN/BTK dual inhibitor with excellent BBB penetration as a potential treatment option for B-NHL. While Bruton’s Tyrosine Kinase (BTK) inhibitors have been approved for the treatment of B-NHL, resistance can emerge due to various mechanisms. This includes acquired mutations at residue C481X of BTK which disrupts covalent BTKi binding, as well as non BTK-driven mutations that seems more common in patients who have failed non-covalent BTKi such as pirtobrutinib. Currently, there is no targeted therapy available to address both resistance mechanisms, highlighting an urgent need for a safe and effective treatment option for patients with r/r B-NHL. 

Potential to overcome resistance to both covalent and non-covalent BTK inhibitors

Preclinical studies have shown that DZD8586 can overcome resistance mutations observed with approved covalent and non-covalent BTK inhibitors. DZD8586 has exhibited potent inhibition of cell growth by blocking both BTK-dependent and BTK-independent signaling pathways.

No BTK inhibitor has been approved for treating diffuse large B-cell lymphoma (DLBCL). It is hypothesized that blockage of BTK pathway alone is not sufficient to bring meaningful clinical benefit in DLBCL. DZD8586 shows strong inhibition of LYN and BTK phosphorylation and achieves superior anti-tumor efficacy in DLBCL and chronic lymphocytic leukemia (CLL) models than selective BTK inhibitors. Due to limited BBB penetration of the current therapies, treatment of central nervous system lymphoma (CNSL) remains a clinical challenge. DZD8586 indicated CNS penetration with the potential to treat CNSL.

A novel treatment option for r/r B-NHL

DZD8586 is currently being evaluated in two phase 1/2 clinical trials for patients with r/r B-NHL worldwide. At 2023 ASH, the pooled analysis from the two studies were debuted. The results revealed that DZD8586 showed encouraging anti-tumor activity with manageable safety and favorable PK profile in heavily pre-treated B-NHL patients. Highlights of the study findings include:

ORR of 64.7% across all dose levels, 71.4% at 50 mg Tumor response in different subtypes, including DLBCL (ORR 83.3%), CNSL, and CLL ORR of 50% in patients resistant to BTKi treatment

"Our research findings presented at ASH demonstrate Dizal’s distinctive competitiveness in the field of hematological oncology. We are fully committed to pushing the boundaries of innovation and developing transformative drugs to improve the lives of patients globally." said Xiaolin Zhang, PhD, Chairman and CEO of Dizal.

–  End –

About golidocitinib (DZD4205)

Golidocitinib is currently the first and only Janus kinase 1 (JAK1) selective inhibitor being evaluated for the treatment of r/r PTCL. At the data cut-off date of August 31, 2023, golidocitinib has demonstrated robust and durable anti-tumor efficacy, with an ORR of 44.3%. More than 50% of the patients with tumor remission achieved a complete response with a CRR of 23.9%. Per IRC assessment, mDoR reached 20.7 months. Golidocitinib was granted Fast Track Designation by the U.S. FDA for the treatment of r/r PTCL in February 2022. In September 2023, the CDE accepted its NDA and granted Priority Review for the treatment of r/r PTCL. The Phase I clinical data of golidocitinib (JACKPOT8 PART A) was published in Annals of Oncology (Impact Factor: 51.8), and global pivotal trial data of golidocitinib for the treatment of r/r PTCL (JACKPOT PART B) was published in The Lancet Oncology (Impact Factor: 54.4).

About DZD8586

DZD8586 is an orally available, highly selective small molecule inhibitor to target both BTK-dependent and BTK-independent B-cell receptor (BCR) signaling pathways, with full blood-brain barrier penetration. Pre-clinical research revealed that DZD8586 demonstrated good safety profile and could effectively inhibit the growth of B-NHL cells. A healthy volunteer study of DZD8586 has been completed to investigate the clinical safety and PK/PD correlation. Additionally, a global phase I/II study is ongoing to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy of DZD8586 in patients with r/r B-NHL. Preliminary results from the clinical trial suggest that DZD8586 exhibits favorable PK properties, good safety profile, and preliminary anti-tumor efficacy in patients with B-NHL.

About Dizal

Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The company aims to develop first-in-class and groundbreaking new medicines, and further address unmet medical needs around the world. Deep-rooted in translational science and molecular design, it has established an internationally competitive portfolio of five clinical-stage assets with two leading assets in global pivotal studies and one already launched. 

To learn more about Dizal, please visit www.dizalpharma.com, or follow us at Linkedin or Twitter.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", and "intend" and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal’s competitive environment, and political, economic, legal, and social conditions.

Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turnout to be incorrect.

Contacts

Investor Relations: [email protected]

Business Development: [email protected]

Source : Dizal Impresses with Its Differentiated Hematological Oncology Portfolio at 2023 ASH

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

HONG KONG, Dec. 12, 2023 /PRNewswire/ — Hong Kong Breast Cancer Foundation (HKBCF) is proud to announce that Dr. Eliza Fok, Chairman of HKBCF, has been honoured with "Women of Power 2023" by leading Hong Kong magazine Prestige Hong Kong.

HKBCF extends its congratulations to Dr. Fok on this achievement. Established in 2005, HKBCF is a non-profit charitable organisation dedicated to promoting breast health education, patient support, research and advocacy in Hong Kong.

"Women of Power 2023" of Prestige Hong Kong aims to recognise successful female leaders who have demonstrated strong cohesive power. Driven by innovation and a pursuit of excellence, they inject new vitality and momentum into the community, driving social development and progress.

During Dr. Fok’s 13-year tenure as Chairman, the HKBCF has consistently progressed and reached new breakthroughs and advancements. Amid the COVID-19 pandemic, the HKBCF transformed its annual flagship fundraising event "Pink Walk" into an online event called "Pink Together" which attracted over 2,000 enthusiastic participants and achieved remarkable results. In April 2021, the HKBCF opened its first Traditional Chinese Medicine clinic at the HKBCF Jockey Club Breast Health Centre (Kowloon), providing breast cancer patients with Traditional Chinese Medicine consultations and treatments to promote the overall well-being of breast cancer patients. In March 2023, the HKBCF opened its Lymphoedema Care Centre to provide holistic lymphoedema care services. Dr. Fok stated, "I am humbled and honoured to be invited as part of Prestige Hong Kong’s "Women of Power 2023"." She added, "Women are the Chief Executive Officer and the Chief Emotional Officer of the family. They play a crucial role as leaders and pillars within families and the community. Women should therefore look after their own health, to bring positive impact to their families and our community. I look forward to learning from the talented female leaders in the group and to work together to contribute back to our community."

Under Dr. Fok’s leadership, the HKBCF has been dedicated to promoting the importance of breast health and maintaining healthy lifestyles among individuals from all walks of life. Guided by the principle of "Early Detection Saves Lives", the HKBCF has embarked on various programmes to raise awareness among women about the importance of regular self-examinations and undergoing mammography screening. The HKBCF has also been actively raising funds to provide free or affordable mammography services to women in the grassroots community and offers a broad range of professional care knowledge and support services to breast cancer patients, their families and caregivers, as well as the survivors.

The HKBCF is also proud to announce that Mrs Yvette Ho, a member of its Advisory Council, is also honoured with "Women of Power 2023" for her dedication in youth education.

The HKBCF will continue to mitigate the threat of breast cancer and safeguard the health and well-being of women and their families, and hence to build a better and healthier Hong Kong.

About Hong Kong Breast Cancer Foundation 
The Hong Kong Breast Cancer Foundation was established on March 8, 2005, making it the first non-profit charitable organisation in Hong Kong dedicated to breast health education, patient support, research, and advocacy. Its mission is to reduce the threat of breast cancer in the local community. The Foundation aims to raise public awareness of breast cancer and promote the importance of breast health, support breast cancer patients on their journey to recovery, and advocate for improvements in breast cancer prevention, control, and medical care in Hong Kong.

Source : Dr. Eliza Fok, Chairman of the Hong Kong Breast Cancer Foundation Is Honoured with "Women of Power 2023" by Prestige Hong Kong

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Double-digit growth of DEKRA’s core business in the first 10 months of 2023 Historic sales record of over four billion euros expected for the full year Despite expectations of subdued global economic development in 2024, DEKRA forecasts additional growth, based on its strong market position in traditional areas, trustful relations with over 500,000 customers globally, and a promising service portfolio for future technologies Business areas Artificial Intelligence and Sustainability to grow at double-digit rates

STUTTGART, Germany, Dec. 12, 2023 /PRNewswire/ — "So far, 2023 has been an excellent year for DEKRA," said Stan Zurkiewicz, DEKRA CEO and Chairman of the Management Board in his preliminary review of the year. "We are very optimistic that we will hit a revenue of over four billion euros in the full year. That is a historic first for DEKRA, and we are very excited." All service divisions and regions are expected to significantly exceed their 2022 sales performance, with some achieving strong double-digit growth.

Beyond excellent business figures, DEKRA reports that its strategy 2025 is on track and bearing fruits. The company has successfully introduced training, advisory, testing, validation and inspection services in its strategic growth areas Artificial Intelligence, Cyber Security, Sustainability, and Future Mobility, establishing itself as strategic partner across the entire value chain of these domains.

While the overall TIC (testing, inspection, and certification) industry is expected to grow by around 5% annually, DEKRA forecasts two-digit growth in its future business areas over the next years. The company is well positioned to exponentially capitalize on this upward trajectory and aims to set itself apart from its competitors. 

Artificial Intelligence (AI): DEKRA supports governments and committees in developing regulatory frameworks

One year after the market introduction of ChatGPT, the potential of generative AI to transform productivity, save lives, reduce inequalities, and more, is evident. "Artificial Intelligence is a true gamechanger. But it cannot be above the game, it has to play by some rules. Without them, this powerful technology may endanger our economies, our health, and even peace," explained DEKRA’s CEO.

DEKRA, based on its deep understanding of technology and data as well as decades of experience in assurance processes, has been invited to advise various governments and committees in the development of such regulatory frameworks. Notably, the company provided guidance to the German Federal Ministry for Digital and Transport concerning the G7 Code of Conduct. Being a completely impartial and independent company, DEKRA does not lobby for any specific language model or technology. "Our focus is exclusively on ensuring that the AI revolution happens in a safe and secure way", Stan Zurkiewicz added.

Governments and institutions around the world are working on regulatory frameworks, with varying priorities. Europe’s Proposal for a Regulation on an Artificial Intelligence Act from 2021, for example, aims to set unified standards in the EU for the introduction, deployment, and use of AI systems, safeguarding individuals’ fundamental rights from potential negative impacts. It sets different rules along different risk levels, from unacceptable to minimal risk. Generally excluded from the use of AI are social scoring, cognitive behavioral manipulation, and real-time facial recognition; the draft is currently being negotiated.

The "Executive Order on Safe, Secure, and Trustworthy Artificial Intelligence", released by the United States of America in October 2023, calls for standards in AI safety and security, adjustments to privacy regulations to address new risks from AI, and actions to protect equity and civil rights. It also builds a bridge to EU legislation. By signing G7’s "Code of Conduct" in October 2023, seven leading industrialized nations – Canada, France, Germany, Italy, Japan, the UK, and the U.S. – committed to developing advanced artificial intelligence systems based on eleven jointly defined principles.

Further globally relevant regulatory initiatives can be found in China, Australia, the United Kingdom, and other regions.

Additionally, in terms of AI normalization, various standardization bodies are dedicated to developing standards for AI systems. 

Service portfolio for testing and validating AI, Cyber Security, and other digital solutions is growing swiftly

In 2023, the company has been among the pioneering TIC companies to put the first wave of AI testing services onto the market. In addition, together with PwC and the city of Hamburg’s innovation fund, DEKRA has formed a joint venture for testing and certification of AI under the name CertifAI.

The company is also delivering on digitizing and automating its services, for instance, when inspecting confined spaces, DEKRA now deploys robots to ensure that human inspectors are not put at risk. Also, via strategic investments in the Swiss-based company Spearhead, DEKRA is capable of giving a first estimate of vehicle damage after a crash fully remotely by instantaneously collecting sensor and telematics data.

"Working with governments, universities, and leading technology companies like Bosch’s AIShield, we are in a prime position to offer testing, inspection, and certification services for Artificial Intelligence and other digital services, most importantly Cyber Security," explained Stan Zurkiewicz. "And that’s exactly the outcome we envisioned in our Strategy 2025. We expect exponential growth in this business area over the coming years, and we plan to remain ahead of our competitors with an unparalleled set of services."

Sustainability: DEKRA strongly supports COP28’s targets, offering over 500 sustainability-related services

DEKRA makes its debut at COP28, the United Nations’ annual climate change conference. The company strongly supports COP28’s targets of tripling renewable energy capacity and doubling energy efficiency improvements across sectors by 2030.

"We need to accelerate climate action. Many of COP28’s targets require cross-national and cross-industry collaboration, and faster innovation cycles may lead to growing risks in safety and security," elaborated DEKRA’s CEO. "We can support key stakeholders in ensuring that the world can accelerate climate action in a safe and secure manner. We are offering over 500 sustainability-related services, from carbon footprint and lifecycle assessments to hydrogen infrastructure inspections as well as ESG auditing and advisory services."

Urging national policymakers to authorize accredited third-party auditing companies for CSRD-related services

In Europe, in response to the German Supply Chain Act ("Lieferkettengesetz") and the Corporate Sustainability Reporting Directive (CSRD), the company expects strong demand for its services portfolio. Yet, regarding CSRD, DEKRA urges national policymakers to allow independent accredited third-party technical auditing companies, such as DEKRA, into this market.

Under CSRD, over 50,000 companies will need to provide sustainability reports by 2026, nearly four times as many as today. Even smaller companies, which do not need to create their own reports, are obliged to share data with their clients. This data needs to be robust, transparent, and verifiable, as external verification will become mandatory under CSRD. In many EU countries, only financial audit firms may be allowed into this market. "Such a way of transposing the EU Directive into national law would result in a serious disadvantage, especially to Europe’s small and medium enterprises," Stan Zurkiewicz pointed out, "as financial audit firms may not have the technical expertise required to report all CSRD-related data in a robust and efficient way. Consequently, the auditing process is likely to be expensive and time consuming."

Future Mobility: DEKRA’s extensive investments are bearing very impressive results

The company’s testing facilities at DEKRA Lausitzring in Klettwitz, Germany, are being rapidly expanded with an objective of establishing, within the next two years, the world’s most comprehensive independent testing site for automated and connected driving. Planned jointly with vehicle manufacturers, suppliers, and research institutions, the new courses now cover more than 80 percent of real traffic scenarios. With the new, unique tracks DEKRA can support its customers even better in testing the safety of their assistance systems and automated driving functions.

Regarding electric vehicles, DEKRA offers a cutting-edge battery test, which delivers highly accurate EV Battery state of health measurement in just a few minutes. It has only recently been recognized with the Innovation Prize of the German Mobility Industry.

Outlook: forecasting further growth in 2024

DEKRA anticipates a volatile macroeconomic situation and difficult framework conditions. However, the company is confident of further growth, based on its strong market position in traditional areas, trustful relations with over 500,000 customers globally, and the promising service portfolio for future technologies.

"We place great trust in the quality of our services, in the people who deliver them, and in our strategic framework. Thus, DEKRA will continue to grow in 2024 and make a significant contribution to making the world safer and more secure," summarized DEKRA’s CEO.

About DEKRA

DEKRA is the world’s largest independent non-listed expert organization in the testing, inspection, and certification sector. As a global provider of comprehensive services and solutions, we help our customers improve their safety, security, and sustainability outcomes. In 2022, DEKRA generated sales totaling nearly EUR 3.8 billion. The company currently employs almost 50,000 people who offer qualified and independent expert services in approximately 60 countries on five continents. With a platinum rating from EcoVadis, DEKRA is now in the top one percent of sustainable businesses ranked.

Source : Despite moderate global growth, DEKRA predicts historic sales record for 2023

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

KUALA LUMPUR, Malaysia, Dec. 12, 2023 /PRNewswire/ — Malaysian International Furniture Fair (MIFF) – the largest and most global furniture trade show in Southeast Asia – held a spectacular gala dinner on Dec 8 to celebrate its 30th anniversary ahead of its 2024 show.

MIFF celebrates 30 Years of connecting the global furniture industry, ahead of its 2024 show, with 500 distinguished guests, loyal exhibitors and business partners on December 8, 2023.

The gathering brought together 500 distinguished guests, loyal exhibitors and business partners to share the remarkable milestones achieved by the annual show, marking a pinnacle for the Malaysian furniture industry.

Gracing the occasion as the Guest-of-Honour was Yang Amat Berhormat Dato’ Sri Fadillah Yusof, Deputy Prime Minister and Minister of Plantation and Commodities.

The glittering Oscar-themed night kicked off the celebrations leading up to next year’s show scheduled from March 1 to 4. 

Established in 1995, MIFF played a pivotal role in expanding the local furniture industry over the years. Recognised as a global top 10 furniture trade event, it is the largest export platform for Malaysian wooden furniture, and office furniture in Southeast Asia.

Since its launch, MIFF has achieved cumulative sales of US$18.4 billion and welcomed 182,000 buyers from 141 countries and regions. It achieved a stellar year in 2023 with a record on-site sale generated of US$1.21 billion and 673 exhibitors.

The award-winning show was founded by now MIFF Chairman Datuk Dr Tan Chin Huat with 152 domestic exhibitors. Foreign exhibitors made their debut in 1999 and their number has been growing exponentially owing to MIFF’s appeal to international buyers.

In lauding the Malaysian furniture industry and local authorities for supporting the show from the start, Datuk Dr Tan said MIFF would continue to be a flagship for Malaysian furniture exports to reinforce the country’s position as a global producer.

"MIFF started as a small show back in 1995. We worked very hard to make it succeed. Today, MIFF is one of the world’s top 10 furniture trade exhibition and the largest in Southeast Asia. For this, I can sincerely say – without the support of the Malaysian furniture industry, MIFF will not be what it is today." said Datuk Dr Tan.

He also paid tribute to the Malaysian government and its agencies for the strong support of MIFF and also to MIFF’s strategic partner, Muar Furniture Association for a fruitful alliance over the past 10 years.

Some 117 loyal exhibitors including companies that have participated for 10 to 30 years (1995-2024) in a row were presented awards in recognition of their unwavering support.

Among them are 17 companies that had exhibited for over 25 years — Boston Office Furniture, C. K. Ban Soon Lee Industries, Chuanheng Furniture Products, Kinheng Furniture, Latitude Tree Furniture, LB Furniture, Merryfair Chair System, Pipesway Furniture, Poh Huat Furniture Industries, Seng Yip Furniture, Seni Daya Woods Industries, Shantawood, Winner Office Network, YB Woodwork Industry, Forest Research Institute Malaysia, Malaysian Timber Council and Malaysian Timber Industry Board.

MIFF 2024 will take place again at the Malaysia International Trade & Exhibition Centre (MITEC) and World Trade Centre Kuala Lumpur (WTCKL) with 17 halls to showcase the array of contemporary designed home furnishings, office and hospitality furniture, accessories, decor, components and materials.

Malaysia’s biggest exporters will be joined by exhibitors from Mainland China, Indonesia, Singapore, South Korea, Taiwan, Thailand, Turkey and Vietnam.

"On behalf of the Muar Furniture Association, I extend our heartiest congratulations to MIFF on its 30th anniversary. This is truly a milestone for MIFF and also the Malaysian furniture industry. MFA is proud to share this journey with MIFF. This is also an opportune time to reaffirm our strategic partnership with MIFF started in 2013. I am confident that MFA and MIFF will maintain the strong momentum in our relationship to create new opportunities for the Malaysian furniture industry." — Mr Steve Ong, President, Muar Furniture Association, MIFF Strategic Partner.

To keep up-to-date or to register as a buyer, visit the MIFF website (www.miff.com.my) For latest news and insights, follow Furnish Now by MIFF (FB).

To contact the MIFF Team, please email: [email protected].

Notes to Editors

About MIFF (www.miff.com.my)
MIFF is the largest and leading export-oriented furniture trade show in Southeast Asia showcasing the widest collection of Made-in-Malaysia wooden furniture, home furniture and office furniture. Since 1995, MIFF is a one-stop platform connecting a wider community of 20,000+ buyers from 140 countries and regions. MIFF is organised by Informa Markets which is a part of Informa PLC, a leading B2B information services group and the largest B2B event organiser in the world.

Source : MALAYSIAN INTERNATIONAL FURNITURE FAIR CELEBRATES 30 YEARS OF GLOBAL TRADE AND EMBRACES THE FUTURE

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network

Identified as a global sustainability leader by S&P Global Committed to generating long-term value for all stakeholders

SHANGHAI, Dec. 12, 2023 /PRNewswire/ — WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been named to the 2023 S&P Dow Jones Sustainability™ World Index (DJSI World) and DJSI Emerging Markets Index, identified as a sustainability leader by S&P Global through its Corporate Sustainability Assessment (CSA).

The S&P Global CSA is an annual evaluation of companies’ sustainability practices, covering more than 10,000 companies from around the world. CSA results inform inclusion in the DJSI, the pioneering index family of global sustainability benchmarks available in the market. WuXi Biologics was ranked number one in its sector in the CSA.

Dr. Chris Chen, WuXi Biologics CEO and Chairman of the ESG Committee, commented, "We are very proud to be included in the DJSI World Index as well as the DJSI Emerging Markets Index. These achievements are a reflection of and recognition for our continuous commitment to enhancing ESG capabilities and further advancing the company’s sustainable growth for the common good of the global community."

WuXi Biologics regards sustainability as the cornerstone of its business development. Across the year, it has made notable ESG achievements. In June, WuXi Biologics became a signatory to the United Nations Global Compact, demonstrating its sustainability commitment. In November, it received an AAA rating from MSCI ESG Ratings. Additionally, it has been awarded the EcoVadis Sustainability Rating’s Platinum Medal, the highest level of recognition granted to the companies being evaluated.

About The Dow Jones Sustainability Indices (DJSI)

DJSI are a family of best-in-class benchmarks for investors who have recognized that sustainable business practices are critical to generating long-term shareholder value and who wish to reflect their sustainability convictions in their investment portfolios. One benchmark, DJSI World, represents the top 10% of the largest 2,500 companies in the S&P Global BMI based on long-term economic, environmental and social criteria.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.

With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2023, WuXi Biologics is supporting 621 integrated client projects, including 22 in commercial manufacturing.

WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

Contacts

ESG
[email protected]

Media
[email protected]

Source : WuXi Biologics Named to 2023 Dow Jones Sustainability World Index

>

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network